Search results
(1 - 9 of 9)
- Title
- Data Migration Tool for CDN XL (semester?), IPRO 349C: Data Migration tool for CDN XL IPRO 349 2.3 Poster S07
- Creator
- Groth, Kristel, Tam, Jonathan, Juda, Damian, Fafara, Lukasz
- Date
- 2007-07, 2007-07
- Description
-
The objective of this IPRO subteam is the improvement of the importation of data to CDN XL in small and medium enterprises sector. This...
Show moreThe objective of this IPRO subteam is the improvement of the importation of data to CDN XL in small and medium enterprises sector. This subteam is working toward the problem of improving the way data is imported from customer to CDN XL (an ERP system). The methodology to be employed is the agile methodology. The expected result of this project is a preliminary software system for importing data from Excel or other heterogeneous files to CDN XL. The goal of the team’s project is to develop a program to for the importation of data from customers to be imported into the CDN XL system to be used by the deployers. The deliverables at the end of the project will be a template for customers, program to extract the data. The team will examine the process of importing the data to develop a program that is generic enough to import different types of data. This project plan is separated into the objective section, where the objective of the subteam is fully explained. In the background section, the background of the project and sponsor are detailed. Also, a diagram of how the CDN XL system works is included. Furthermore, the technology used and possible ethical issues are addressed. The third section describes the methodology being used. The way documentation of work is also addressed in this section. In addition, the risk management and quality assurance will be addressed in this section. The expected results are explained in the fourth section – the form it is in as well as potential products that might arise from this project. In the sixth section, the tasks, duration of each task and milestones are included. The team members are introduced in the seventh section. Finally, in the last section, the designation of roles – what each team member is responsible for – is detailed.
Sponsorship: Comarch
Deliverables for IPRI 349C: Data Migration Tool for CDN XL for the Summer 2007 semester
Show less
- Title
- Data Migration Tool for CDN XL (semester?), IPRO 349C: Data Migration tool for CDN XL IPRO 349 2.3 Project Plan S07
- Creator
- Groth, Kristel, Tam, Jonathan, Juda, Damian, Fafara, Lukasz
- Date
- 2007-07, 2007-07
- Description
-
The objective of this IPRO subteam is the improvement of the importation of data to CDN XL in small and medium enterprises sector. This...
Show moreThe objective of this IPRO subteam is the improvement of the importation of data to CDN XL in small and medium enterprises sector. This subteam is working toward the problem of improving the way data is imported from customer to CDN XL (an ERP system). The methodology to be employed is the agile methodology. The expected result of this project is a preliminary software system for importing data from Excel or other heterogeneous files to CDN XL. The goal of the team’s project is to develop a program to for the importation of data from customers to be imported into the CDN XL system to be used by the deployers. The deliverables at the end of the project will be a template for customers, program to extract the data. The team will examine the process of importing the data to develop a program that is generic enough to import different types of data. This project plan is separated into the objective section, where the objective of the subteam is fully explained. In the background section, the background of the project and sponsor are detailed. Also, a diagram of how the CDN XL system works is included. Furthermore, the technology used and possible ethical issues are addressed. The third section describes the methodology being used. The way documentation of work is also addressed in this section. In addition, the risk management and quality assurance will be addressed in this section. The expected results are explained in the fourth section – the form it is in as well as potential products that might arise from this project. In the sixth section, the tasks, duration of each task and milestones are included. The team members are introduced in the seventh section. Finally, in the last section, the designation of roles – what each team member is responsible for – is detailed.
Sponsorship: Comarch
Deliverables for IPRI 349C: Data Migration Tool for CDN XL for the Summer 2007 semester
Show less
- Title
- Data Migration Tool for CDN XL (semester?), IPRO 349C
- Creator
- Groth, Kristel, Tam, Jonathan, Juda, Damian, Fafara, Lukasz
- Date
- 2007-07, 2007-07
- Description
-
The objective of this IPRO subteam is the improvement of the importation of data to CDN XL in small and medium enterprises sector. This...
Show moreThe objective of this IPRO subteam is the improvement of the importation of data to CDN XL in small and medium enterprises sector. This subteam is working toward the problem of improving the way data is imported from customer to CDN XL (an ERP system). The methodology to be employed is the agile methodology. The expected result of this project is a preliminary software system for importing data from Excel or other heterogeneous files to CDN XL. The goal of the team’s project is to develop a program to for the importation of data from customers to be imported into the CDN XL system to be used by the deployers. The deliverables at the end of the project will be a template for customers, program to extract the data. The team will examine the process of importing the data to develop a program that is generic enough to import different types of data. This project plan is separated into the objective section, where the objective of the subteam is fully explained. In the background section, the background of the project and sponsor are detailed. Also, a diagram of how the CDN XL system works is included. Furthermore, the technology used and possible ethical issues are addressed. The third section describes the methodology being used. The way documentation of work is also addressed in this section. In addition, the risk management and quality assurance will be addressed in this section. The expected results are explained in the fourth section – the form it is in as well as potential products that might arise from this project. In the sixth section, the tasks, duration of each task and milestones are included. The team members are introduced in the seventh section. Finally, in the last section, the designation of roles – what each team member is responsible for – is detailed.
Sponsorship: Comarch
Deliverables for IPRI 349C: Data Migration Tool for CDN XL for the Summer 2007 semester
Show less
- Title
- ACCELPharma (semester?), IPRO 353: ACCELPharma IPRO 353 IPRO Day Presentation F06
- Creator
- Josefsson, Gustaf, Ames, Kerry, Calizo, Milagros, Schiller, Brian, Groth, Kristel, Ervin, Natalia, Holmes, Matt, Lee, Hyun, Lim, Eung, Ravi, Iyengar
- Date
- 2006-12, 2006-12
- Description
-
AccelPharma intends to enable pharmaceutical and biotech companies to reintroduce withdrawn drugs to the market place through the development,...
Show moreAccelPharma intends to enable pharmaceutical and biotech companies to reintroduce withdrawn drugs to the market place through the development, validation, and deployment of personalized medicine models. It differentiates itself by being one of the only companies to correlate side effects of drugs to certain genetic mutations for a broad range of effects. AccelPharma expects to break even and begin to achieve positive revenues after only the second sale.
Deliverables for IPRO 353: ACCELPharma for the Fall 2006 semester.
Show less
- Title
- ACCELPharma (semester?), IPRO 353: ACCELPharma IPRO 353 Abstract F06
- Creator
- Josefsson, Gustaf, Ames, Kerry, Calizo, Milagros, Schiller, Brian, Groth, Kristel, Ervin, Natalia, Holmes, Matt, Lee, Hyun, Lim, Eung, Ravi, Iyengar
- Date
- 2006-12, 2006-12
- Description
-
AccelPharma intends to enable pharmaceutical and biotech companies to reintroduce withdrawn drugs to the market place through the development,...
Show moreAccelPharma intends to enable pharmaceutical and biotech companies to reintroduce withdrawn drugs to the market place through the development, validation, and deployment of personalized medicine models. It differentiates itself by being one of the only companies to correlate side effects of drugs to certain genetic mutations for a broad range of effects. AccelPharma expects to break even and begin to achieve positive revenues after only the second sale.
Deliverables for IPRO 353: ACCELPharma for the Fall 2006 semester.
Show less
- Title
- ACCELPharma (semester?), IPRO 353: ACCELPharma IPRO 353 Poster F06
- Creator
- Josefsson, Gustaf, Ames, Kerry, Calizo, Milagros, Schiller, Brian, Groth, Kristel, Ervin, Natalia, Holmes, Matt, Lee, Hyun, Lim, Eung, Ravi, Iyengar
- Date
- 2006-12, 2006-12
- Description
-
AccelPharma intends to enable pharmaceutical and biotech companies to reintroduce withdrawn drugs to the market place through the development,...
Show moreAccelPharma intends to enable pharmaceutical and biotech companies to reintroduce withdrawn drugs to the market place through the development, validation, and deployment of personalized medicine models. It differentiates itself by being one of the only companies to correlate side effects of drugs to certain genetic mutations for a broad range of effects. AccelPharma expects to break even and begin to achieve positive revenues after only the second sale.
Deliverables for IPRO 353: ACCELPharma for the Fall 2006 semester.
Show less
- Title
- ACCELPharma (semester?), IPRO 353: ACCELPharma IPRO 353 Midterm Presentation F06
- Creator
- Josefsson, Gustaf, Ames, Kerry, Calizo, Milagros, Schiller, Brian, Groth, Kristel, Ervin, Natalia, Holmes, Matt, Lee, Hyun, Lim, Eung, Ravi, Iyengar
- Date
- 2006-12, 2006-12
- Description
-
AccelPharma intends to enable pharmaceutical and biotech companies to reintroduce withdrawn drugs to the market place through the development,...
Show moreAccelPharma intends to enable pharmaceutical and biotech companies to reintroduce withdrawn drugs to the market place through the development, validation, and deployment of personalized medicine models. It differentiates itself by being one of the only companies to correlate side effects of drugs to certain genetic mutations for a broad range of effects. AccelPharma expects to break even and begin to achieve positive revenues after only the second sale.
Deliverables for IPRO 353: ACCELPharma for the Fall 2006 semester.
Show less
- Title
- ACCELPharma (semester?), IPRO 353
- Creator
- Josefsson, Gustaf, Ames, Kerry, Calizo, Milagros, Schiller, Brian, Groth, Kristel, Ervin, Natalia, Holmes, Matt, Lee, Hyun, Lim, Eung, Ravi, Iyengar
- Date
- 2006-12, 2006-12
- Description
-
AccelPharma intends to enable pharmaceutical and biotech companies to reintroduce withdrawn drugs to the market place through the development,...
Show moreAccelPharma intends to enable pharmaceutical and biotech companies to reintroduce withdrawn drugs to the market place through the development, validation, and deployment of personalized medicine models. It differentiates itself by being one of the only companies to correlate side effects of drugs to certain genetic mutations for a broad range of effects. AccelPharma expects to break even and begin to achieve positive revenues after only the second sale.
Deliverables for IPRO 353: ACCELPharma for the Fall 2006 semester.
Show less
- Title
- ACCELPharma (semester?), IPRO 353: ACCELPharma IPRO 353 Final Report F06
- Creator
- Josefsson, Gustaf, Ames, Kerry, Calizo, Milagros, Schiller, Brian, Groth, Kristel, Ervin, Natalia, Holmes, Matt, Lee, Hyun, Lim, Eung, Ravi, Iyengar
- Date
- 2006-12, 2006-12
- Description
-
AccelPharma intends to enable pharmaceutical and biotech companies to reintroduce withdrawn drugs to the market place through the development,...
Show moreAccelPharma intends to enable pharmaceutical and biotech companies to reintroduce withdrawn drugs to the market place through the development, validation, and deployment of personalized medicine models. It differentiates itself by being one of the only companies to correlate side effects of drugs to certain genetic mutations for a broad range of effects. AccelPharma expects to break even and begin to achieve positive revenues after only the second sale.
Deliverables for IPRO 353: ACCELPharma for the Fall 2006 semester.
Show less